Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shenzhen Neptunus Interlong Bio-Technique Co EV-to-FCF?
Shenzhen Neptunus Interlong Bio-Technique CoHKSE:08329 -5.71% EV-to-FCF is 0.97 as of Sep. 16, 2026, which is 56% below its 10-year median of 2.22. The stock has 3 warning signs investors should review. Among 567 Drug Manufacturers companies, Shenzhen Neptunus Interlong Bio-Technique Co ranks better than 96.83% on this metric.
HKSE:08329's EV-to-FCF is ranked better than 96.83% of 567
companies
in the Drug Manufacturers industry
Industry Median: 18.91
vs HKSE:08329: 0.97
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shenzhen Neptunus Interlong Bio-Technique Co's PE Ratio (TTM) for today is calculated as:
Shenzhen Neptunus Interlong Bio-Technique Co's share price for today is HK$0.099.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shenzhen Neptunus Interlong Bio-Technique Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was HK$-0.034.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shenzhen Neptunus Interlong Bio-Technique Co EV-to-FCF Related Terms
Shenzhen Neptunus Interlong Bio-Technique Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co EV-to-FCF Chart
Shenzhen Neptunus Interlong Bio-Technique Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Neptunus Interlong Bio-Technique Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Neptunus Interlong Bio-Technique Co EV-to-FCF vs Drug Manufacturers Industry
Shenzhen Neptunus Interlong Bio-Technique Co's current Enterprise Value is HK$95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Shenzhen Neptunus Interlong Bio-Technique Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was HK$97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) has a EV-to-FCF of 0.97 as of Sep. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. This is 56% below median its historical median of 2.22. According to the industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #18 out of 567 companies in the Drug Manufacturers industry, placing it in the top 3.2%.
Is Shenzhen Neptunus Interlong Bio-Technique Co's EV-to-FCF too high?
Shenzhen Neptunus Interlong Bio-Technique Co's current EV-to-FCF of 0.97 is 56% below median its 10-year median of 2.22. The Drug Manufacturers industry median EV-to-FCF is 18.91. Shenzhen Neptunus Interlong Bio-Technique Co's value of 0.97 is 94.9% below this industry median. Based on the distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #18 out of 567 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Shenzhen Neptunus Interlong Bio-Technique Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Neptunus Interlong Bio-Technique Co ranks #18 out of 567 companies for EV-to-FCF. This places Shenzhen Neptunus Interlong Bio-Technique Co in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 18.91. Shenzhen Neptunus Interlong Bio-Technique Co's value of 0.97 is 94.9% below this benchmark. While the company's 10-year median is 2.22 vs. the industry median of 18.91, Shenzhen Neptunus Interlong Bio-Technique Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 18.91, based on 567 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shenzhen Neptunus Interlong Bio-Technique Co's current EV-to-FCF of 0.97 is 94.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shenzhen Neptunus Interlong Bio-Technique Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 18.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shenzhen Neptunus Interlong Bio-Technique Co's current EV-to-FCF is 0.97, which is 56% below median its own 10-year median of 2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Neptunus Interlong Bio-Technique Co stock overvalued right now?
Based on GuruFocus' analysis, Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.10 — trading 29.3% below its estimated fair value. The current EV-to-FCF is 0.97, which is 56% below median its 10-year median of 2.22 and 94.9% below the Drug Manufacturers industry median of 18.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shenzhen Neptunus Interlong Bio-Technique Co (HKSE:08329), the current EV-to-FCF is 0.97 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shenzhen Neptunus Interlong Bio-Technique Co Ltd is engaged in the research and development, manufacturing, and selling of medicines and medical devices. It is also involved in the purchase and sale of medicines and healthcare food products. The group's revenue and results from operations are mainly derived from activities in the PRC. The operating segments of the company are the Manufacturing and selling of medicines and medical devices; and the Sales and distribution of medicines, healthcare products, and medical devices.. The majority of revenue is generated from the Manufacturing and selling of medicines and medical devices segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08329 has been successfully added to your 
